Creative Enterprise Holdings Limited announced that with effect on 30 July 2021 Dr. Deng Wei Dong has been appointed as a non-executive Director and designated as the chairman of the Board. Accordingly, Mr. Poon Kin Leung has resigned as the chairman of the Board whilst still maintaining his position as an executive Director; Mr. Zhong Tao has been appointed as a non-executive Director; Mr. Wong For Yam has been appointed as a non-executive Director; and Dr. Jing Tao has been appointed as a non-executive Director. Dr. Deng Wei Dong has been appointed as a non-executive Director and chairman of the Board on 30 July 2021. Dr. Deng currently serves as the Head of the Capital Investment and Management Department of CMG and has been a director of the Offeror since 9 March 2021. Mr. Zhong Tao, has been appointed as a non-executive Director on 30 July 2021. Mr. Zhong joined the CMG group in 1993 and has served as Deputy General Manager of Finance Department at CMG since 2015, General Manager at China Merchants International Finance Company Limited since 2005 and a director at China Merchants Group Finance Co. Ltd. since 2017. Mr. Zhong is primarily responsible for formulating financing strategies for the CMG group and maintaining and managing financial institution relationships. Mr. Wong For Yam, has been appointed as a non-executive Director on 30 July 2021. Mr. Wong currently serves as the Deputy Head of the Human Resources Department of CMG since August 2015. Mr. Wong has over 34 years of experience in financial management and human resources management. Mr. Wong joined the CMG group in June 1987, serving in the Dr. Jing Tao, has been appointed as a non-executive Director on 30 July 2021. Dr. Jing joined CMG in June 2012 where she currently serves as the Senior Managing Director of the Capital Investment and Management Department. She is primarily responsible for implementing mergers and acquisitions, including accessing the opportunities, designing deal structures, leading the negotiations, coordinating external advisors and internal colleagues to do feasibility research, following up on the internal and external regulatory approval.